Stock Track | Glaukos Plunges 12% as iDose Sales Growth Disappoints Despite Reaffirmed 2026 Guidance

Stock Track

Jan 14

Glaukos (GKOS) shares plummeted 12% intraday after the company reported weaker-than-expected sequential revenue growth for its iDose product in Q4 2025, overshadowing its reaffirmed 2026 net sales guidance of $600 million to $620 million.

The medtech firm projected Q4 iDose sales of about $45 million, representing a 13% sequential increase from Q3, which fell short of some analysts' expectations. Needham analyst David Saxon noted that seasonal factors and a strong Q3 made the sequential growth appear weaker, but the market reacted negatively to the slowdown.

While Glaukos maintained its 2026 revenue outlook and reported strong preliminary Q4 net sales of $143 million (up 36% YoY), investors focused on the iDose performance, driving the stock lower.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140850833"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140850833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140850833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140850833","market":"us","top_or_hot":-1,"title":"Stock Track | Glaukos Plunges 12% as iDose Sales Growth Disappoints Despite Reaffirmed 2026 Guidance","media":"Stock Track","content":"<p>Glaukos (GKOS) shares plummeted 12% intraday after the company reported weaker-than-expected sequential revenue growth for its iDose product in Q4 2025, overshadowing its reaffirmed 2026 net sales guidance of $600 million to $620 million.</p><p>The medtech firm projected Q4 iDose sales of about $45 million, representing a 13% sequential increase from Q3, which fell short of some analysts' expectations. Needham analyst David Saxon noted that seasonal factors and a strong Q3 made the sequential growth appear weaker, but the market reacted negatively to the slowdown.</p><p>While Glaukos maintained its 2026 revenue outlook and reported strong preliminary Q4 net sales of $143 million (up 36% YoY), investors focused on the iDose performance, driving the stock lower.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Glaukos Plunges 12% as iDose Sales Growth Disappoints Despite Reaffirmed 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Glaukos Plunges 12% as iDose Sales Growth Disappoints Despite Reaffirmed 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-14 16:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Glaukos (GKOS) shares plummeted 12% intraday after the company reported weaker-than-expected sequential revenue growth for its iDose product in Q4 2025, overshadowing its reaffirmed 2026 net sales guidance of $600 million to $620 million.</p><p>The medtech firm projected Q4 iDose sales of about $45 million, representing a 13% sequential increase from Q3, which fell short of some analysts' expectations. Needham analyst David Saxon noted that seasonal factors and a strong Q3 made the sequential growth appear weaker, but the market reacted negatively to the slowdown.</p><p>While Glaukos maintained its 2026 revenue outlook and reported strong preliminary Q4 net sales of $143 million (up 36% YoY), investors focused on the iDose performance, driving the stock lower.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GKOS","symbol_name":"Glaukos Corp","start_time":0,"source_url":"","article_id":"1140850833","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140850833","pubTimestamp":1768379789,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Glaukos (GKOS) shares plummeted 12% intraday after the company reported weaker-than-expected sequential revenue growth for its iDose product in Q4 2025, overshadowing its reaffirmed 2026 net sales...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GKOS":"Glaukos Corp"},"translate_title":"股票追踪|尽管重申了2026年指引，但iDose销售增长令人失望，Glaukos暴跌12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":1},"content_text":"Glaukos (GKOS) shares plummeted 12% intraday after the company reported weaker-than-expected sequential revenue growth for its iDose product in Q4 2025, overshadowing its reaffirmed 2026 net sales guidance of $600 million to $620 million.The medtech firm projected Q4 iDose sales of about $45 million, representing a 13% sequential increase from Q3, which fell short of some analysts' expectations. Needham analyst David Saxon noted that seasonal factors and a strong Q3 made the sequential growth appear weaker, but the market reacted negatively to the slowdown.While Glaukos maintained its 2026 revenue outlook and reported strong preliminary Q4 net sales of $143 million (up 36% YoY), investors focused on the iDose performance, driving the stock lower.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}